FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira

WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab.

Related Keywords

Washington ,United States ,Amgen Amjevita ,Kostenloser Wertpapierhandel ,Boehringer Ingelheim Cyltezo ,Boehringer Ingelheim ,Drug Administration ,Cyltezo ,First ,Interchangeable ,Biosimilar ,Humira ,